Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Creve Coeur, Maryland Clinical Trials

A listing of Creve Coeur, Maryland clinical trials actively recruiting patient volunteers.

RESULTS

Found (15) clinical trials

A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer

This is an open label, Phase 1b pre-operative window of opportunity biomarker trial to analyze the combination of intravenous (IV) anti-PD-1 inhibitor, nivolumab, given along with toll-like receptor 8 (TLR 8) agonist motolimod delivered either subcutaneously (SC) or by intratumoral injection (IT) in subjects with squamous cell carcinoma of the ...

Phase

9.44 miles

Learn More »

Lenalidomide Adherence in Older Adults

To describe patterns of adherence and pilot baseline measures to investigate factors associated with lower adherence to lenalidomide in older adults with myeloma.

Phase N/A

9.44 miles

Learn More »

A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC)

This study is designed to evaluate how the body processes and removes mirikizumab. The study will also evaluate safety and disease response in pediatric participants with UC taking mirikizumab. The study will last about 52 weeks and may include up to 17 visits.

Phase

9.44 miles

Learn More »

Radicava (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)

Treatment will be prescribed by HCPs in accordance with their clinical judgement and the prescribing information for Edaravone. The decision to prescribe Edaravone to the participants should be made separately from the decision to enroll then in the study. There will be no randomized assignments to treatment and no restrictions ...

Phase N/A

9.44 miles

Learn More »

High-Risk Skin Cancers With Atezolizumab Plus NT-I7

This is a Phase 1b/2a, open-label, multicenter study to evaluate the safety, tolerability and anti-tumor effect of NT-I7 (rhIL-7-hyFc) in combination with atezolizumab (MPDL3280A, anti-PD-L1) in patients with anti-PD-1/PD-L1 nave or relapsed/refractory high-risk skin cancers including cutaneous Squamous Cell Carcinoma (cSCC), Merkel Cell Carcinoma (MCC) and melanoma. This study has ...

Phase

9.44 miles

Learn More »